J&J Hoping To Position Simeprevir As Top Next-Gen Protease Inhibitor For HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma’s Janssen Research & Development unit has filed protease inhibitor simeprevir for approval in the U.S., Europe and Japan, recently receiving notification of priority review from FDA; meanwhile, the company waits to see if its compound will be used in combination with Bristol’s daclatasvir or Gilead’s sofosbuvir.